Kimberly-Clark Closes Mega-Acquisition of Kenvue and Unveils $3.1B Restructuring Program

Executive Summary

On November 2, 2026, Kimberly-Clark Corporation (K-C) filed a Form 8-K reporting the consummation of its acquisition of Kenvue Inc., alongside substantial post-merger integration initiatives, executive compensation packages, board changes, and bylaw amendments.

---

Key Transaction & Corporate Developments

1. Completion of Kenvue Acquisition (Item 2.01)

• Merger Structure: Kenvue merged into a direct subsidiary of K-C, ultimately surviving as Kenvue LLC.
• Consideration: Each share of Kenvue Common Stock was converted into the right to receive:
  • 0.14625 shares of K-C Common Stock ($1.25 par value).
  • $3.50 in cash.
• Aggregate Dilution: K-C delivered or has an obligation to deliver approximately 281,060,840 shares of K-C Common Stock in connection with the closing.
• Treatment of Equity Awards: Outstanding Kenvue options, RSUs, PSUs, and DSUs were converted into K-C equity awards based on an Equity Award Exchange Ratio, with PSUs converting into time-vesting RSUs.

2. Kenvue Integration Program Costs (Item 2.05)

• On October 30, 2026, K-C's Board approved the Kenvue Integration Program targeting operating profit synergies through 2030.
• Pre-Tax Charges: Expected cumulative pre-tax charges of approximately $3.1 billion ($2.5 billion in cash and $0.6 billion non-cash) through December 31, 2029.
  • Supply chain network optimization: ~$0.8 billion cash (plus non-cash charges).
  • ERP and technology integration: ~$0.6 billion cash.
  • Workforce optimization: ~$0.4 billion cash.
  • Advisory services: ~$0.4 billion cash.
  • Program management & other: ~$0.3 billion cash.
• Capital Expenditures: Expected spend of approximately $1.4 billion through December 31, 2029.

3. Board of Directors Governance Changes (Item 5.02)

• Appointments: Pursuant to the merger agreement, three former Kenvue directors were appointed to the K-C Board:
  • Richard E. Allison, Jr. (appointed to Audit Committee)
  • Larry J. Merlo (appointed to Management Development & Compensation and Nominating & Corporate Governance Committees)
  • Kirk L. Perry
• Resignations: Dr. Mae C. Jemison, Christa S. Quarles, and Jaime Ramirez resigned from the Board to create vacancies for the Kenvue designees, with no disagreements reported.

4. Performance Recognition & Incentive Awards (Item 5.02)

On October 30, 2026, the Compensation Committee approved premium-priced nonqualified stock options effective December 1, 2026, vesting on December 1, 2029, with a 10-year term and an exercise price of at least the greater of $120.00 or 110% of the Grant Date closing price:

• Michael Hsu (Chairman & CEO): $6,600,000 grant value
• Nelson Urdaneta (SVP & CFO): $2,150,000 grant value
• Jeffrey Melucci (Chief Strategy, Business Development and Administrative Officer): $1,800,000 grant value

5. Corporate Bylaw Amendments (Item 5.03)

Effective November 2, 2026, K-C amended its By-Laws to update advance notice provisions, align with SEC Rule 14a-19 universal proxy requirements, modernize remote meeting procedures, update quorum and committee provisions, eliminate demands for written ballots by 10% holders, and adopt an exclusive federal forum selection clause for Securities Act claims.

---

Market & Strategic Impact

This transaction represents a transformational consumer health and personal care consolidation. The scale of the integration charges ($3.1B) and capital requirements ($1.4B) will significantly impact K-C's near-to-medium-term GAAP earnings, cash flows, and capital allocation strategy while unlocking targeted long-term operating profit synergies.